Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Richard Schwab

    TitleAssociate Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0820
    CA La Jolla 92093
    Phone858-657-5090
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Research Interests
      Dr. Schwab's research focuses on biomarkers to diagnosis and refine the treatment of cancer. His current projects include precision oncology using DNA sequencing, target discovery using RNA sequencing, and validation of novel cancer initiating cell markers.

      In support of these, and future, biomarker studies Dr. Schwab co-directs a biorepository to prospectively collect de-identified blood, urine and tumor specimens. This resource has a series of key features to maximize its future utility; (1) specimens are associated with detailed clinical data that is regularly updated, (2) three methods to ensure follow up data are available are used, including social security number queries to the national databases, (3) samples are stored as small volume aliquots at –80 degrees Celsius to prevent freeze/thaw damage, (4) subjects are consented for germ line DNA sequencing (5) buffy coat is stored in nucleic acid stabilizing solution and (6) through a collaboration with The Jackson Laboratory patient derived xenografts are generated.

      Education and Training
      BA - Molecular and Cell Biology, University of California, Berkeley - 1995
      MD - Albert Einstein College of Medicine - 2000
      Residency - Internal Medicine, University of California, San Diego - 2003
      Fellowship - Hematology/Oncology, University of California, San Diego - 2006


      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. D Antonio M, Weghorn D, D Antonio-Chronowska A, Coulet F, Olson KM, DeBoever C, Drees F, Arias A, Alakus H, Richardson AL, Schwab R, Farley EK, Sunyaev SR, Frazer KA. Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. Nat Commun. 2017 Sep 05; 8(1):436. PMID: 28874753.
        View in: PubMed
      2. Martínez ME, Gomez SL, Tao L, Cress R, Rodriguez D, Unkart J, Schwab R, Nodora JN, Cook L, Komenaka I, Li C. Erratum to: Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2017 Sep 04. PMID: 28871561.
        View in: PubMed
      3. Martínez ME, Gomez SL, Tao L, Cress R, Rodriguez D, Unkart J, Schwab R, Nodora JN, Cook L, Komenaka I, Li C. Contribution of clinical and socioeconomic factors to differences in breast cancer subtype and mortality between Hispanic and non-Hispanic white women. Breast Cancer Res Treat. 2017 Jul 11. PMID: 28698973.
        View in: PubMed
      4. Martínez ME, Unkart JT, Tao L, Kroenke CH, Schwab R, Komenaka I, Gomez SL. Prognostic significance of marital status in breast cancer survival: A population-based study. PLoS One. 2017; 12(5):e0175515. PMID: 28475579.
        View in: PubMed
      5. Nodora JN, Komenaka IK, Bouton ME, Ohno-Machado L, Schwab R, Kim HE, Farcas C, Perez G, Elena Martinez M. Biospecimen Sharing Among Hispanic Women in a Safety-Net Clinic: Implications for the Precision Medicine Initiative. J Natl Cancer Inst. 2017 02; 109(2). PMID: 27688295.
        View in: PubMed
      6. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.
        View in: PubMed
      7. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. PMID: 27406347.
        View in: PubMed
      8. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab R, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
        View in: PubMed
      9. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab R, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. PMID: 26848768; PMCID: PMC4891078.
      10. Schwaederle M, Parker BA, Schwab R, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr; 15(4):743-52. PMID: 26873727.
        View in: PubMed
      11. Komenaka IK, Nodora JN, Madlensky L, Winton LM, Heberer MA, Schwab R, Weitzel JN, Martinez ME. Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. J Community Genet. 2016 Jul; 7(3):177-83. PMID: 26690931; PMCID: PMC4960024.
      12. Bao L, Messer K, Schwab R, Harismendy O, Pu M, Crain B, Yost S, Frazer KA, Rana B, Hasteh F, Wallace A, Parker BA. Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors. PLoS One. 2015; 10(11):e0142487. PMID: 26554380; PMCID: PMC4640562.
      13. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab R, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
      14. Schwab R, Kato S, Crain B, Pu M, Messer K, Weidner N, Blair SL, Wallace AM, Carson DA, Parker BA. A window-of-opportunity biomarker study of etodolac in resectable breast cancer. Cancer Med. 2015 Oct; 4(10):1583-8. PMID: 26275572; PMCID: PMC4618628.
      15. Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab R, Kurzrock R. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. PMID: 26243651.
        View in: PubMed
      16. Mausbach BT, Schwab R, Irwin SA. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015 Jul; 152(2):239-46. PMID: 26077640; PMCID: PMC4861253.
      17. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015; 14(13):2121-8. PMID: 25950492; PMCID: PMC4614941.
      18. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab R, Shimabukuro KA, Parker BA, Kurzrock R. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther. 2015 Jun; 14(6):1488-94. PMID: 25852059.
        View in: PubMed
      19. Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab R, Shimabukuro KA, Parker BA, Kurzrock R. Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget. 2015 Feb 20; 6(5):3033-42. PMID: 25596748; PMCID: PMC4413635.
      20. Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab R, Shimabukuro KA, Parker BA, Kurzrock R. Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer. Cell Cycle. 2015; 14(11):1730-7. PMID: 25928476; PMCID: PMC4614790.
      21. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):17266-71. PMID: 25411317; PMCID: PMC4260559.
      22. Baker JL, Schwab R, Wallace AM, Madlensky L. Breast cancer in a RAD51D mutation carrier: case report and review of the literature. Clin Breast Cancer. 2015 Feb; 15(1):e71-5. PMID: 25445424.
        View in: PubMed
      23. Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab R, Peterson MR, Lowy AM, Frazer KA, Harismendy O. Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014; 6(7):53. PMID: 25228923; PMCID: PMC4165363.
      24. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab R, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):969-74. PMID: 24994917.
        View in: PubMed
      25. Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab R, Peterson MR, Lowy AM, Frazer KA, Harismendy O. Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med. 2014; 6(5):43. PMID: 24944587; PMCID: PMC4062050.
      26. Schwaederle M, Parker BA, Schwab R, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist. 2014 Jun; 19(6):631-6. PMID: 24797821; PMCID: PMC4041669.
      27. Yan M, Parker BA, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014 Jul; 40(6):770-80. PMID: 24656976.
        View in: PubMed
      28. Sicklick JK, Leonard SY, Babicky ML, Tang CM, Mose ES, French RP, Jaquish DV, Hoh CK, Peterson M, Schwab R, Lowy AM. Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. J Transl Med. 2014 Feb 10; 12:41. PMID: 24507750; PMCID: PMC3930355.
      29. Anderson KN, Schwab R, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014 Feb; 144(1):1-10. PMID: 24477977; PMCID: PMC4026199.
      30. Harismendy O, Schwab R, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA. Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res. 2013 Dec 10; 15(6):R115. PMID: 24326041; PMCID: PMC3978701.
      31. Patel A, Schwab R, Liu YT, Bafna V. Amplification and thrifty single-molecule sequencing of recurrent somatic structural variations. Genome Res. 2014 Feb; 24(2):318-28. PMID: 24307551; PMCID: PMC3912422.
      32. Grando A, Schwab R. Building and evaluating an ontology-based tool for reasoning about consent permission. AMIA Annu Symp Proc. 2013; 2013:514-23. PMID: 24551354; PMCID: PMC3900195.
      33. Martinez ME, Wertheim BC, Natarajan L, Schwab R, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Komenaka IK, Thompson PA. Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1853-61. PMID: 23950213; PMCID: PMC3799795.
      34. Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab R, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS One. 2013; 8(6):e67258. PMID: 23826249; PMCID: PMC3695076.
      35. Yost SE, Alakus H, Matsui H, Schwab R, Jepsen K, Frazer KA, Harismendy O. Mutascope: sensitive detection of somatic mutations from deep amplicon sequencing. Bioinformatics. 2013 Aug 01; 29(15):1908-9. PMID: 23712659; PMCID: PMC3712217.
      36. Barrett CL, Schwab R, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One. 2013; 8(3):e58714. PMID: 23527012; PMCID: PMC3604164.
      37. Padler-Karavani V, Song X, Yu H, Hurtado-Ziola N, Huang S, Muthana S, Chokhawala HA, Cheng J, Verhagen A, Langereis MA, Kleene R, Schachner M, de Groot RJ, Lasanajak Y, Matsuda H, Schwab R, Chen X, Smith DF, Cummings RD, Varki A. Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem. 2012 Jun 29; 287(27):22593-608. PMID: 22549775; PMCID: PMC3391140.
      38. Yost SE, Smith EN, Schwab R, Bao L, Jung H, Wang X, Voest E, Pierce JP, Messer K, Parker BA, Harismendy O, Frazer KA. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res. 2012 Aug; 40(14):e107. PMID: 22492626; PMCID: PMC3413110.
      39. Paul AK, Schwab R. Efficacy and pharmacogenomic biomarkers in breast cancer. Biomark Med. 2012 Apr; 6(2):211-21. PMID: 22448796.
        View in: PubMed
      40. Harismendy O, Schwab R, Bao L, Olson J, Rozenzhak S, Kotsopoulos SK, Pond S, Crain B, Chee MS, Messer K, Link DR, Frazer KA. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol. 2011 Dec 20; 12(12):R124. PMID: 22185227; PMCID: PMC3334619.
      41. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 2011 May 01; 71(9):3352-63. PMID: 21505105; PMCID: PMC3085609.
      42. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CC, Rosenbach MD, Corr M, Schwab R, Carson DA. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010 Apr 20; 107(16):7479-84. PMID: 20368435; PMCID: PMC2867719.